Title: Local Treatment of Non-Small-Cell Lung Cancer by Dry Powder Inhaler: A Spray Dried Bevacizumab Formulation

Kimberly B. Shepard, PhD
Lonza (Bend, Oregon, USA)

Webinar content

• Local treatment of lung cancer by the inhalation route has the potential to improve patient compliance, reduce treatment costs and even reduce dose.
• Dry powder inhalers (DPIs) are the most popular device for lung delivery in a patient-friendly, shelf-stable package.
• Spray drying is used to enable particle engineering of delicate molecules, such as monoclonal antibodies (mAbs), for use in DPIs.
• Here we present a case study using an inhaled formulation of bevacizumab, a mAb VEGF-inhibitor formulated via spray drying. It was tested in a pre-clinical rat model of NSCLC and found to reduce tumor burden as effectively as injections.

About the presenter

• Kim Shepard is a Principal Engineer at Lonza’s Bend, OR site, where she has worked for 7 years. Her work in the R&D group has focused on developing new processes, formulations and technologies in the areas of inhalation particle engineering and bioavailability enhancement for oral delivery, focusing particularly on spray drying.
• She received her PhD in chemical engineering from Princeton University, studying the polymer physics and amorphous materials.
• Kim also received a B.E. and M.E. in chemical engineering from Stevens Institute of Technology.